Overview

Study With Vortioxetine on Emotional Functioning in Patients With Depression

Status:
Completed
Trial end date:
2020-02-21
Target enrollment:
Participant gender:
Summary
The study will evaluate effectiveness of flexible dose vortioxetine 10-20 mg/day on emotional functioning in patients with MDD with an inadequate response to SSRIs/SNRIs.
Phase:
Phase 4
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Vortioxetine